» Articles » PMID: 17213331

Misassembled Mutant DeltaF508 CFTR in the Distal Secretory Pathway Alters Cellular Lipid Trafficking

Overview
Journal J Cell Sci
Specialty Cell Biology
Date 2007 Jan 11
PMID 17213331
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Most patients with cystic fibrosis (CF) have a single codon deletion (DeltaF508) in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) that impairs assembly of the multidomain glycoprotein. The mutant protein escapes endoplasmic reticulum (ER) quality control at low temperature, but is rapidly cleared from the distal secretory pathway and degraded in lysosomes. CF cells accumulate free cholesterol similar to Niemann-Pick disease type C cells. We show that this lipid alteration is caused by the presence of misassembled mutant CFTR proteins, including DeltaF508, in the distal secretory pathway rather than the absence of functional CFTR. By contrast, cholesterol distribution is not changed by either D572N CFTR, which does not mature even at low temperature, or G551D, which is processed normally but is inactive. On expression of the DeltaF508 mutant, cholesterol and glycosphingolipids accumulate in punctate endosomal structures and cholesterol esters are reduced, indicating a block in the translocation of cholesterol to the ER for esterification. This is overcome by Rab9 overexpression, resulting in clearance of accumulating intracellular cholesterol. Similar but less pronounced alterations in intracellular cholesterol distribution are observed on expression of a temperature-rescued mutant variant of the related ATP-binding cassette (ABC) protein multidrug resistance-associated protein 1 (MRP1). Thus, on escape from ER quality control, misassembled mutants of CFTR and MRP1 impair lipid homeostasis in endocytic compartments.

Citing Articles

Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment.

Castaldo A, Iacotucci P, Bagnasco S, Fevola C, Carnovale V, Antonelli F Sci Rep. 2024; 14(1):17422.

PMID: 39075279 PMC: 11286749. DOI: 10.1038/s41598-024-68511-7.


One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes.

Castaldo A, Gelzo M, Iacotucci P, Longobardi A, Taccetti G, Terlizzi V Front Mol Biosci. 2024; 10:1327958.

PMID: 38259684 PMC: 10800484. DOI: 10.3389/fmolb.2023.1327958.


Reduced Sphingosine in Cystic Fibrosis Increases Susceptibility to Infections.

Schnitker F, Liu Y, Keitsch S, Soddemann M, Verhasselt H, Kehrmann J Int J Mol Sci. 2023; 24(18).

PMID: 37762308 PMC: 10530875. DOI: 10.3390/ijms241814004.


Essential Fatty Acid Deficiency in Cystic Fibrosis Disease Progression: Role of Genotype and Sex.

Shrestha N, McCarron A, Rout-Pitt N, Donnelley M, Parsons D, Hryciw D Nutrients. 2022; 14(21).

PMID: 36364928 PMC: 9657825. DOI: 10.3390/nu14214666.


Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs.

Abu-Arish A, Pandzic E, Luo Y, Sato Y, Turner M, Wiseman P J Cell Sci. 2022; 135(5).

PMID: 35060604 PMC: 8976878. DOI: 10.1242/jcs.259002.